Chaitanya Tatineni

Chaitanya is the CEO of Curium’s International Markets & Chief M&A Officer for the Group. He leads Curium’s PET, SPECT and Therapy operations in international markets – outside of the US, Canada, and Western Europe – with a focus on building the Company’s presence in China and Japan. In his capacity as the Chief M&A Officer, Chaitanya is responsible for defining and executing the group’s inorganic growth initiatives, including M&A, in-licensing and strategic collaborations. Chaitanya is a member of Curium’s Executive Committee.

Prior to joining Curium, Chaitanya had more that 11 years of professional experience in investment banking, and had executed more than 20 transactions for pharmaceuticals, diagnostics and healthcare services clients across the US, Europe, and Asia. He has previously worked for the healthcare investment banking teams at Jefferies, Bank of America Merrill Lynch and ABN AMRO banks in both London and Hong Kong.

Chiatanya holds and MBA from the Indian Institute of Management Ahmedabad and a bachelor’s degree in Electronics and Communication Engineering from the Indian Institute of Technology, Kharagpur.